ApconiX Opens a New Office in Sweden

ApconiX is excited to announce the opening of our new office in Sweden.  The subsidiary ApconiX AB will be located at AstraZeneca’s BioVentureHub in Mölndal, Gothenburg.

ApconiX was formed by Dr Richard Knight, Dr Michael Morton and Professor Ruth Roberts in 2015 and is based at Alderley Park in Cheshire, U.K.   The co-founders have established a company recognised for its expertise in nonclinical safety toxicology and ion channel electrophysiology.  “The addition of two experienced and renowned toxicologists, Björn Dahl and Steffen Ernst in our Gothenburg office, will provide a great opportunity to engage with biotech and pharma clients, not just in Sweden but across Scandinavia and Northern Europe”, commented Richard.

“ApconiX provides a global service in nonclinical drug safety.  It is our aim to continue to grow internationally.   Working with companies across the globe is easy today, but we know that proximity is very helpful in understanding the needs of individual clients”, added Ruth.

ApconiX have a team of scientific experts helping customers in all aspects of drug safety including project toxicology, nonclinical study monitoring, target safety assessments as well as ion channel screening.   “Whether in the research or development phase, this unique combination provides our clients with the right advice at the right time to make better decisions on drug safety”, noted Mike.

AstraZeneca established the BioVentureHub in 2014 with the aim to stimulate innovation and strengthen competitiveness in life sciences in Sweden and Scandinavia.  Placed at the centre of AstraZeneca Gothenburg, BVH companies are part of a unique, open and collaborative scientific community.

Magnus Björsne CEO of BVH believes, “By daring to share and by stimulating a 4D life science reality – combining Drugs, Diagnostics, Devices, Digital health – we are forming a modern, life science environment based on scientific curiosity and collaboration opportunities.”

By |2019-02-07T12:13:15+00:00February 7th, 2019|Ion Channels, Target Safety Assessments, Toxicology, Events|Comments Off on ApconiX Opens a New Office in Sweden

About the Author:

Dr Richard Knight PhD, ERT, is a Director and Co-founder of ApconiX, a preclinical toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts. Richard graduated from the University of Bradford in 1989 with a degree in Biomedical Sciences (Pharmacology) before gaining a PhD at the University of Leeds researching the role of adenosine receptors in renal function and toxicity. His research then included post-doctoral studies at University of California, Los Angeles (UCLA) into the effects of ischaemia/reperfusion injury on cardiac metabolism. Richard joined Zeneca Pharmaceuticals, Safety of Medicines Group in 1996 as a Study Director, and then Project Toxicologist across multiple therapy areas, from early discovery through to market. As Lead Toxicologist for Oncology, Richard was a member of both the Drug Safety and Metabolism, and Oncology Leadership teams with responsibility for safety across the AZ oncology portfolio. In this senior role he provided leadership and mentoring support to other project toxicologists. Richard has worked on many drug platforms over this time including small molecules, biologics, proteins and oligonucleotides and has been involved in bringing over 30 new candidate drugs into clinical trials and 5 to marketing approval.